Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

A parallel study of careHPV and Hybrid Capture 2 human papillomavirus DNA testing for cervical cancer screening in rural China.

Lin CQ, Chen F, Liu B, Zhang YZ, Cui XL, Li AM, Zhang WH, Chen W, Chang I, Sivasubramaniam P, Zhu J, Qiao YL.

J Virol Methods. 2014 Jun;202:73-8. doi: 10.1016/j.jviromet.2014.03.002. Epub 2014 Mar 15.

PMID:
24642241
2.

Optimal positive cutoff points for careHPV testing of clinician- and self-collected specimens in primary cervical cancer screening: an analysis from rural China.

Kang LN, Jeronimo J, Qiao YL, Zhao FH, Chen W, Valdez M, Zhang X, Bansil P, Paul P, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE.

J Clin Microbiol. 2014 Jun;52(6):1954-61. doi: 10.1128/JCM.03432-13. Epub 2014 Mar 26.

3.

The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens.

Chen W, Jeronimo J, Zhao FH, Qiao YL, Valdez M, Zhang X, Kang LN, Bansil P, Paul P, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE.

J Clin Virol. 2014 Dec;61(4):553-7. doi: 10.1016/j.jcv.2014.09.018. Epub 2014 Oct 7.

PMID:
25453572
4.

Comparison of careHPV and hybrid capture 2 assays for detection of high-risk human Papillomavirus DNA in cervical samples from HIV-1-infected African women.

Ngou J, Magooa MP, Gilham C, Djigma F, Didelot MN, Kelly H, Yonli A, Sawadogo B, Lewis DA, Delany-Moretlwe S, Mayaud P, Segondy M; HARP Study Group.

J Clin Microbiol. 2013 Dec;51(12):4240-2. doi: 10.1128/JCM.02144-13. Epub 2013 Oct 9.

5.

A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China.

Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, Chen F, Pan QJ, Lorincz AT.

Lancet Oncol. 2008 Oct;9(10):929-36. doi: 10.1016/S1470-2045(08)70210-9. Epub 2008 Sep 19.

PMID:
18805733
6.

An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China.

Zhao FH, Jeronimo J, Qiao YL, Schweizer J, Chen W, Valdez M, Lu P, Zhang X, Kang LN, Bansil P, Paul P, Mahoney C, Berard-Bergery M, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE.

Cancer Prev Res (Phila). 2013 Sep;6(9):938-48. doi: 10.1158/1940-6207.CAPR-13-0091. Epub 2013 Jul 22.

7.

Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobasĀ® HPV Test results from the ATHENA study.

Rao A, Sandri MT, Sideri M, Young S, Sharma A, Behrens C.

J Clin Virol. 2013 Sep;58(1):161-7. doi: 10.1016/j.jcv.2013.06.041. Epub 2013 Jul 27.

PMID:
23895930
8.

Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.

Jentschke M, Soergel P, Hillemanns P.

J Virol Methods. 2013 Oct;193(1):131-4. doi: 10.1016/j.jviromet.2013.05.009. Epub 2013 May 23.

PMID:
23707925
9.

Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening.

Depuydt CE, Benoy IH, Beert JF, Criel AM, Bogers JJ, Arbyn M.

J Clin Microbiol. 2012 Dec;50(12):4073-7. doi: 10.1128/JCM.01231-12. Epub 2012 Oct 10.

10.

Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.

Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burroni E, Frayle-Salamanca H, Giorgi Rossi P, Pierotti P, Ronco G; New Technologies for Cervical Cancer Screening Working Group.

J Clin Microbiol. 2013 Sep;51(9):2901-7. doi: 10.1128/JCM.01047-13. Epub 2013 Jun 26.

11.

Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.

Poljak M, Ostrbenk A, Seme K, Ucakar V, Hillemanns P, Bokal EV, Jancar N, Klavs I.

J Clin Microbiol. 2011 May;49(5):1721-9. doi: 10.1128/JCM.00012-11. Epub 2011 Mar 23.

12.

Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection.

Kwon MJ, Roh KH, Park H, Woo HY.

J Clin Virol. 2014 Apr;59(4):246-9. doi: 10.1016/j.jcv.2014.01.015. Epub 2014 Jan 30.

PMID:
24568964
13.

Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.

Carozzi FM, Burroni E, Bisanzi S, Puliti D, Confortini M, Giorgi Rossi P, Sani C, Scalisi A, Chini F.

J Clin Microbiol. 2011 Apr;49(4):1446-51. doi: 10.1128/JCM.02311-10. Epub 2011 Feb 16.

14.
15.

Comparative performance of human papillomavirus DNA testing using novel sample collection methods.

Gage JC, Partridge EE, Rausa A, Gravitt PE, Wacholder S, Schiffman M, Scarinci I, Castle PE.

J Clin Microbiol. 2011 Dec;49(12):4185-9. doi: 10.1128/JCM.01254-11. Epub 2011 Oct 12.

16.

[Cost-effectiveness analysis on the once-in-a-lifetime cervical cancer screening program for women living in rural and urban areas of China].

Xu H, Zhao FH, Gao XH, Hu SY, Chen JF, Liu ZH, Xu XL, Gao LM, Liu QG, Ma L, Liu YJ, Qiao YL.

Zhonghua Liu Xing Bing Xue Za Zhi. 2013 Apr;34(4):399-403. Chinese.

PMID:
23937850
17.

[Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].

Li RZ, Shi JF, Zhou QZ, Wu RF, Li N, Wu LN, Zhou YQ, Wang Q, Liu ZH, Liu B, Qiao YL.

Zhonghua Yi Xue Za Zhi. 2006 Feb 7;86(5):307-11. Chinese.

PMID:
16677522
18.

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.

Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Review. Erratum in: Vaccine. 2013 Dec 16;31(52):6266.

PMID:
23199969
19.

Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.

Hesselink AT, Berkhof J, van der Salm ML, van Splunter AP, Geelen TH, van Kemenade FJ, Bleeker MG, Heideman DA.

J Clin Microbiol. 2014 Mar;52(3):890-6. doi: 10.1128/JCM.03195-13. Epub 2014 Jan 3.

20.

Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.

Shi JF, Canfell K, Lew JB, Zhao FH, Legood R, Ning Y, Simonella L, Ma L, Kang YJ, Zhang YZ, Smith MA, Chen JF, Feng XX, Qiao YL.

BMC Cancer. 2011 Jun 13;11:239. doi: 10.1186/1471-2407-11-239.

Supplemental Content

Support Center